Henriette A C Kyrieleis

Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children.

W. Oyen, J. Wetzels, E. Levtchenko, 2009, Clinical journal of the American Society of Nephrology : CJASN.

A new blood group antigen is defined by anti‐CD59, detected in a CD59‐deficient patient

W. Flegel, M. Anliker, H. Schrezenmeier, 2014, Transfusion.

Targeted therapy with eculizumab for inherited CD59 deficiency.

U. Pannicke, H. Schrezenmeier, C. Dohna-Schwake, 2014, The New England journal of medicine.

Homozygous frameshift mutations in FAT1 cause a syndrome characterized by colobomatous-microphthalmia, ptosis, nephropathy and syndactyly

V. Lougaris, A. Plebani, S. Lyonnet, 2019, Nature Communications.

FAT1 mutations cause a glomerulotubular nephropathy

T. Chan, R. Lifton, D. Milford, 2016, Nature Communications.

Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome.

J. Wetzels, E. Levtchenko, Henriette A C Kyrieleis, 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A new blood group antigen is defined by anti‐CD59, detected in a CD59‐deficient patient

W. Flegel, M. Anliker, H. Schrezenmeier, 2014, Transfusion.

Targeted therapy with eculizumab for inherited CD59 deficiency.

U. Pannicke, H. Schrezenmeier, C. Dohna-Schwake, 2014, The New England journal of medicine.

Homozygous frameshift mutations in FAT1 cause a syndrome characterized by colobomatous-microphthalmia, ptosis, nephropathy and syndactyly

V. Lougaris, A. Plebani, S. Lyonnet, 2019, Nature Communications.